IL-1β and IL-10: diagnostic and prognostic potential of cytokines in the assessment of progression of non-alcoholic fatty liver disease in patients with hypertension

Keywords: kallistatin, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, hypertension, IL-10, IL-1β


Non-alcoholic fatty liver disease (NAFLD) affects about a quarter of the world's population and it is closely linked to hypertension (HT). Pro-inflammatory and anti-inflammatory cytokines play a key role in the pathology progression, and the search for non-invasive biomarkers for the diagnosis of NAFLD remains an important issue.

The aim of the study was to determine the diagnostic and prognostic value of IL-1β and IL-10 in assessing the progression of liver parenchyma changes in patients with NAFLD and HT comorbidity.

Materials and methods. A study of 115 patients with non-alcoholic steatohepatitis (NASH) was performed. The main group consisted of 63 patients with NASH and HT, 52 patients with isolated NAFLD represented the comparison group. Clinical and laboratory parameters were evaluated, IL-10 and IL-1β levels were measured by ELISA method, ultrasound steatometry and elastography were performed in all patients.

Results. The attenuation coefficient and median liver stiffness in NAFLD and HT group significantly exceeded the results in the isolated NAFLD group and in the control group. The IL-1β level in NAFLD and HT group was 17.55 pg/ml, and in isolated NAFLD group the indicator averaged 15.72 pg/ml, which exceeded the control values (8.26 pg/ml). IL-10 level was 12.69 pg/ml and 14.34 pg/ml in patients with comorbid and isolated NAFLD, respectively, while control results averaged 16.19 pg/ml. It were found strong relationship between IL-1β, IL-10 and CRP levels in patients with NAFLD and HT (r=0.61, p=0.024, and r=-0.69, p=0.036, respectively). Inverse correlations were also found between the cytokines IL-1β and IL-10 in NAFLD patients with and without HT (r=-0.61, p<0.001, and r=-0.57, p<0.001, respectively). Changes in the cytokine status of patients with NAFLD at different stages of steatosis and liver fibrosis had been identified.

Conclusions. The presence of concomitant HT in patients with NAFLD is associated with greater severity of liver parenchyma changes. NAFLD manifestation is accompanied by increase of IL-1β and decrease of IL-10 levels, and deepening of these deviations were found in patients with comorbidity of NAFLD and HT.

Interleukins IL-1β and IL-10 can be defined as biomarkers of NAFLD progression both in its isolated course and in its comorbidity with HT. The possibility of using biomarkers as an independent non-invasive test of diagnosing NAFLD requires further study.


Download data is not yet available.

Author Biographies

Natalia Zhelezniakova, Kharkiv National Medical University

Department of Internal Medicine No. 1

Anastasiia Rozhdestvenska, Kharkiv National Medical University

Department of Internal Medicine No. 1


Babak, O., Bashkirova, A. (2019). Cluster analysis of the pathogenetic relationships of metabolic parameters in patients with non-alcoholic fatty liver disease on the background of hypertension. World Science, 10 (50), 30‒36. doi:

De Vries, M., Westerink, J., Kaasjager, K. H. A. H., de Valk, H. W. (2020). Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism, 105 (12), 3842–3853. doi:

Maida, M., Macaluso, F., Salomone, F., Petta, S. (2016). Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature. Current Molecular Medicine, 16 (8), 721–737. doi:

Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., Barbui, C. (2016). Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology, 65 (3), 589–600. doi:

Kasper, P., Martin, A., Lang, S., Demir, M., Steffen, H.-M. (2021). Hypertension in NAFLD: An uncontrolled burden. Journal of Hepatology, 74 (5), 1258–1260. doi:

Braunersreuther, V. (2012). Role of cytokines and chemokines in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 18 (8), 727–735. doi:

Mannaa, F. A., Abdel-Wahhab, K. G. (2016). Physiological potential of cytokines and liver damages. Hepatoma Research, 2 (6), 131–143. doi:

Mitra, S., De, A., Chowdhury, A. (2020). Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational Gastroenterology and Hepatology, 5, 16. doi:

Nelson, J. E., Handa, P., Aouizerat, B., Wilson, L., Vemulakonda, L. A. et. al. (2016). Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Alimentary Pharmacology & Therapeutics, 44 (11-12), 1253–1264. doi:

Tilg, H., Effenberger, M., Adolph, T. E. (2019). A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? Expert Opinion on Investigational Drugs, 29 (2), 103–106. doi:

Barbier, L., Ferhat, M., Salamé, E., Robin, A., Herbelin, A., Gombert, J.-M. et. al. (2019). Interleukin-1 Family Cytokines: Keystones in Liver Inflammatory Diseases. Frontiers in Immunology, 10. doi:

Chiriac, S., Stanciu, C., Girleanu, I., Cojocariu, C., Sfarti, C., Singeap, A.-M. et. al. (2021). Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Canadian Journal of Gastroenterology and Hepatology, 2021, 1–11. doi:

Steen, E. H., Wang, X., Balaji, S., Butte, M. J., Bollyky, P. L., Keswani, S. G. (2020). The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Advances in Wound Care, 9 (4), 184–198. doi:

Bocsan, I. C., Milaciu, M. V., Pop, R. M., Vesa, S. C., Ciumarnean, L., Matei, D. M., Buzoianu, A. D. (2017). Cytokines Genotype-Phenotype Correlation in Nonalcoholic Steatohepatitis. Oxidative Medicine and Cellular Longevity, 2017, 1–7. doi:

Saraiva, M., Vieira, P., O’Garra, A. (2019). Biology and therapeutic potential of interleukin-10. Journal of Experimental Medicine, 217 (1). doi:

Krishnan, S. M., Sobey, C. G., Latz, E., Mansell, A., Drummond, G. R. (2014). IL-1β and IL-18: inflammatory markers or mediators of hypertension? British journal of pharmacology, 171 (24), 5589–5602. doi:

Lima, V. V., Zemse, S. M., Chiao, C.-W., Bomfim, G. F., Tostes, R. C., Clinton Webb, R., Giachini, F. R. (2016). Interleukin-10 limits increased blood pressure and vascular RhoA/Rho-kinase signaling in angiotensin II-infused mice. Life Sciences, 15 (145), 137–143. doi:

Castera, L., Forns, X., Alberti, A. (2008). Non-invasive evaluation of liver fibrosis using transient elastography. Journal of Hepatology, 48 (5), 835–847. doi:

Evans, J. (1996). Straight forward statistics for the behavioral sciences. Brooks/Cole Pub. Co – Pacific Grove – CA.

Luan, J., Chen, W., Fan, J., Wang, S., Zhang, X., Zai, W. et. al. (2020). GSDMD membrane pore is critical for IL-1β release and antagonizing IL-1β by hepatocyte-specific nanobiologics is a promising therapeutics for murine alcoholic steatohepatitis. Biomaterials, 227, 119570. doi:

De Miranda-Henriques, M. S., Falcão Carlos,, F., Ramalho Trigueiro, A. P., Pimentel de Sousa, A. W., Silva Andrade, K. da. (2019). Role of cytokines in pathogenesis and progression of nonalcoholic steatohepatitis. Gastroenterology & Hepatology: Open Access, 10 (3), 126–130. doi:

👁 28
⬇ 33
How to Cite
Zhelezniakova, N., & Rozhdestvenska, A. (2021). IL-1β and IL-10: diagnostic and prognostic potential of cytokines in the assessment of progression of non-alcoholic fatty liver disease in patients with hypertension. EUREKA: Health Sciences, (5), 17-26.
Medicine and Dentistry